Evidence map›Paper›PMID 31417863›Full record

ArticleFrontiers in oncology2019

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer.

Akshita B Bhatt, Mohit Gupta, Van T Hoang, Suravi Chakrabarty, Thomas D Wright, Steven Elliot, Ishveen K Chopra, Darlene Monlish, Katie Anna, Matthew E Burow and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Frontiers in oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Akshita B BhattDivision of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Mohit GuptaDivision of Medicinal Chemistry, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Van T HoangDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, United States.
Suravi ChakrabartyDivision of Medicinal Chemistry, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Thomas D WrightDivision of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Steven ElliotDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, United States.
Ishveen K ChopraDivision of Medicinal Chemistry, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Darlene MonlishDivision of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Katie AnnaDivision of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Matthew E BurowDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, United States.
Jane E CavanaughDivision of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Patrick T FlahertyDivision of Medicinal Chemistry, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States.
Duquesne University · USTulane Medical Center · USTulane University · US

Funding

Kinase mediated suppression of metastasis in breast cancerR01CA174785 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI COLLINS-BUROW, BRIDGETTE MICHELLE · 2016 to 2020
$1.8M
Novel small molecule inhibitors of MEK5_ERK5 for the treatment of breast cancerR15CA176496 · NCI · DUQUESNE UNIVERSITY · PI CAVANAUGH, JANE E · 2014 to 2014
$394k
NCI NIH HHS R01 CA174785NCI NIH HHS R15 CA176496
6 · The paper itself

Abstract

Epithelial to mesenchymal transition (EMT) is a cellular program that converts non-motile epithelial cells into invasive mesenchymal cells. EMT is implicated in cancer metastasis, chemo-resistance, cancer progression, and generation of cancer stem cells (CSCs). Inducing mesenchymal to epithelial transition (MET), the reverse phenomenon of EMT, is proposed as a novel strategy to target triple negative and tamoxifen-resistant breast cancer. Triple negative breast cancer (TNBC) is characterized by the loss of hormone receptors, a highly invasive mesenchymal phenotype, and a lack of targeted therapy. Estrogen receptor-positive breast cancer can be targeted by tamoxifen, an ER antagonist. However, these cells undergo EMT over the course of treatment and develop resistance. Thus, there is an urgent need to develop therapeutic interventions to target these aggressive cancers. In this study, we examined the role of novel diphenylamine analogs in converting the mesenchymal phenotype of MDA-MB-231 TNBC cells to a lesser aggressive epithelial phenotype. Using analog-based drug design, a series of diphenylamine analogs were synthesized and initially evaluated for their effect on E-cadherin protein expression and changes incell morphology, which was quantified by measuring the spindle index (SI) value. Selected compound

Indexed as

EMTMAPKmesenchymalMETphenotypic switchTNBC

Identifiers

PMID31417863
PMCPMC6682674
OpenAlexW2959432596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.